About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg (OP:RLFTF)

0.2581 +0.0144 (+5.91%)
Streaming Delayed Price Updated: 10:49 AM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Relief Therapeutics Hldg

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
Via ACCESS Newswire
News headline image
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
Via ACCESS Newswire
News headline image
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Via ACCESS Newswire
News headline image
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Via ACCESSWIRE
News headline image
Relief Therapeutics Publishes 2025 Half-Year Report
Via ACCESS Newswire
News headline image
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Via ACCESS Newswire
News headline image
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Via ACCESS Newswire
News headline image
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Results of Annual General Meeting
Via ACCESS Newswire
News headline image
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Via ACCESS Newswire
News headline image
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Via ACCESS Newswire
News headline image
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Via ACCESS Newswire
News headline image
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Via ACCESS Newswire
News headline image
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
News headline image
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Via ACCESSWIRE
News headline image
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Via ACCESSWIRE
News headline image
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
News headline image
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Via ACCESSWIRE
News headline image
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.